» Articles » PMID: 28861421

The Role of Reactive Oxygen Species in Myocardial Redox Signaling and Regulation

Abstract

Reactive oxygen species (ROS) are subcellular messengers in gene regulatory and signal transduction pathways. In pathological situations, ROS accumulate due to excessive production or insufficient degradation, leading to oxidative stress (OS). OS causes oxidation of DNA, membranes, cellular lipids, and proteins, impairing their normal function and leading ultimately to cell death. OS in the heart is increased in response to ischemia/reperfusion, hypertrophy, and heart failure. The concentration of ROS is determined by their rates of production and clearance by antioxidants. Increases in OS in heart failure are primarily a result of the functional uncoupling of the respiratory chain due to inactivation of complex I. However, increased ROS in the failing myocardium may also be caused by impaired antioxidant capacity, such as decreased activity of Cu/Zn superoxide dismutase (SOD) and catalase (CAT) or stimulation of enzymatic sources, including, cyclooxygenase, xanthine oxidase (XO), nitric oxide synthase, and nonphagocytic NAD(P)H oxidases (Noxs). Mitochondria are the main source of ROS during heart failure and aging. Increased production of ROS in the failing heart leads to mitochondrial permeability transition, which results in matrix swelling, outer membrane rupture, a release of apoptotic signaling molecules, and irreversible injury to the mitochondria. Alterations of "redox homeostasis" leads to major cellular consequences, and cellular survival requires an optimal regulation of the redox balance.

Citing Articles

Insulin Resistance and Estimated 10-Year Risk of a First Hard Cardiovascular Event.

Yang Z, Shi J, He S Curr Med Sci. 2025; 45(1):51-56.

PMID: 39998770 DOI: 10.1007/s11596-025-00024-4.


An optimized Langendorff-free method for isolation and characterization of primary adult cardiomyocytes.

Nikouee A, Yap J, Rademacher D, Kim M, Zang Q BMC Cardiovasc Disord. 2024; 24(1):649.

PMID: 39548395 PMC: 11566262. DOI: 10.1186/s12872-024-04256-5.


Risk of anthracycline-induced cardiac dysfunction in adolescent and young adult (AYA) cancer survivors: role of genetic susceptibility loci.

Stafford L, Tang X, Brandt A, Ma J, Banchs J, Livingston J Pharmacogenomics J. 2024; 24(4):21.

PMID: 38951505 PMC: 11824427. DOI: 10.1038/s41397-024-00343-0.


Class I and II Histone Deacetylase Inhibitors as Therapeutic Modulators of Dilated Cardiac Tissue-Derived Mesenchymal Stem/Stromal Cells.

Miksiunas R, Labeit S, Bironaite D Int J Mol Sci. 2024; 25(12).

PMID: 38928463 PMC: 11203858. DOI: 10.3390/ijms25126758.


Atrial fibrillation in cancer, anticancer therapies, and underlying mechanisms.

Shaaban A, Scott S, Greenlee A, Binda N, Noor A, Webb A J Mol Cell Cardiol. 2024; 194:118-132.

PMID: 38897563 PMC: 11500699. DOI: 10.1016/j.yjmcc.2024.06.005.


References
1.
Zima A, Blatter L . Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res. 2006; 71(2):310-21. DOI: 10.1016/j.cardiores.2006.02.019. View

2.
Umar S, van der Laarse A . Nitric oxide and nitric oxide synthase isoforms in the normal, hypertrophic, and failing heart. Mol Cell Biochem. 2009; 333(1-2):191-201. DOI: 10.1007/s11010-009-0219-x. View

3.
Shen E, Li Y, Li Y, Shan L, Zhu H, Feng Q . Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes. 2009; 58(10):2386-95. PMC: 2750234. DOI: 10.2337/db08-0617. View

4.
Aoki H, Kang P, Hampe J, Yoshimura K, Noma T, Matsuzaki M . Direct activation of mitochondrial apoptosis machinery by c-Jun N-terminal kinase in adult cardiac myocytes. J Biol Chem. 2002; 277(12):10244-50. DOI: 10.1074/jbc.M112355200. View

5.
Griendling K, FitzGerald G . Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 2003; 108(16):1912-6. DOI: 10.1161/01.CIR.0000093660.86242.BB. View